Article · Wikipedia archive · Last revised Jul 26, 2026

RG-7410

RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed. Its route of administration was unspecified.

Last revised
Jul 26, 2026
Read time
≈ 1 min
Length
146 w
Citations
11
Source
Wikipedia ↗
RG-7410
Clinical data
Other namesRG7410
Routes of
administration		Unspecified1
Drug classTrace amine-associated receptor 1 (TAAR1) agonist1
Identifiers
CAS Number

RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.12 Its route of administration was unspecified.1

The drug reached phase 1 clinical trials prior to the discontinuation of its development.12 It was under development by Hoffmann-La Roche.12 RG-7410 was first disclosed by January 20143 and a phase 1 trial was reported to have been completed by October 2014.4

See also

See also

References

References

  1. "RG 7410". AdisInsight. 13 October 2015. Retrieved 23 October 2024.
  2. "Delving into the Latest Updates on RG-7410 with Synapse". Synapse. 19 September 2024. Retrieved 23 October 2024.
  3. "Roche 2013 results" (PDF). Roche Group. London. 30 January 2014.
  4. "Pipeline summary" (PDF). Roche Group. Changes to the development pipeline Q3 2014 update